Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Subscribe To Our Newsletter & Stay Updated
